• SELECT SITE CURRENCY
Select a currency for use throughout the site
Parkinson's Disease Partnering 2007-2012
CurrentPartnering, June 2012, Pages: 100
The Parkinsons Disease Partnering 2007-2012 provides understanding and access to the Parkinsons disease partnering deals and agreements entered into by the worlds leading healthcare companies .
The report provides an analysis of Parkinsons disease partnering deals. The majority of deals are discovery or development stage whereby the licensee obtains a right or an option right to license the licensors Parkinsons disease technology. These deals tend to be multicomponent, starting with collaborative R&D, and commercialization of outcomes.
Understanding the flexibility of a prospective partners negotiated deals terms provides critical insight into the negotiation process in terms of what you can expect to achieve during the negotiation of terms. Whilst many smaller companies will be seeking details of the payments clauses, the devil is in the detail in terms of how payments are triggered contract documents provide this insight where press releases do not.
This data driven report contains over 110 links to online copies of actual Parkinsons disease deals and contract documents as submitted to the Securities Exchange Commission by companies and their partners, where available. Contract documents provide the answers to numerous questions about a prospective partners flexibility on a wide range of important issues, many of which will have a significant impact on each partys ability to derive value from the deal.
The initial chapters of this report provide an orientation of Parkinsons disease partnering trends.
Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in Parkinsons disease partnering since 2007, including a summary of deals by industry sector, stage of development, deal type, and technology type. Numerous tables provide outline financial trends.
Chapter 3 provides an overview of the leading Parkinsons disease deals since 2007. Deals are listed by headline value, signed by bigpharma, most active bigpharma. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.
Chapter 4 provides a comprehensive directory of Parkinsons disease partnering deals signed and announced since 2007. The chapter is organized by company A-Z, stage of development at signing, deal type (collaborative R&D, co-promotion, licensing etc), and technology type. Each deal title links via Weblink to an online version of the deal record, and where available the contract document, providing easy access to each contract document on demand.
In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the
research, development and commercialization of Parkinsons disease technologies and products.
Parkinsons Disease Partnering 2007-2012 is intended to provide the reader with an in-depth understanding and access to Parkinsons disease trends and structure of deals entered into by leading companies worldwide.
This data driven report includes:
Trends in Parkinsons disease dealmaking in the biopharma industry since 2007
Access to summary headline, upfront, milestone and royalty data
The leading Parkinsons disease deals by value since 2007
In Parkinsons Disease Partnering 2007-2012, the available deals are listed by:
Upfront payment value
Royalty rate value
Stage of development at signing
Deal component type
Each deal title links via Weblink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.
Parkinson's Disease Partnering 2007-2012 provides the reader with the following key benefits:
In-depth understanding of Parkinson's disease deal trends since 2007
Access to summary headline, upfront, milestone and royalty data
Comprehensive access to over 110 actual Parkinson's disease deals entered into by the worlds biopharma companies since 2007
Insight into key deal terms included in contracts, where disclosed
Understand the key deal terms companies have agreed in deals
Undertake due diligence to assess suitability of your proposed deal terms for partner companies
Chapter 1 - Introduction
Chapter 2 - Trends in Parkinson's disease partnering
2.2. Parkinson's disease partnering over the years
2.3. Bigpharma Parkinson's disease dealmaking activity
2.4. Parkinson's disease partnering by deal type
2.5. Parkinson's disease partnering industry sector
2.6. Parkinson's disease partnering by stage of development
2.7. Parkinson's disease partnering by technology type
2.8. Disclosed financial deal terms for Parkinson's disease partnering
2.8.1 Parkinson's disease headline values
2.8.2 Parkinson's disease upfront payments
2.8.3 Parkinson's disease milestone payments
2.8.4 Parkinson's disease royalty rates
Chapter 3 - Leading Parkinson's disease deals
3.2. Top Parkinson's disease deals by value
3.3. Top Parkinson's disease deals involving bigpharma
Chapter 4 - Dealmaking directory
4.2. Company A-Z
4.3. By deal type
4.4. By industry sector
4.5. By stage of development
4.6. By technology type
Diagnostic - companion
In vitro models
Chapter 5 - Partnering resource center
5.1. Online partnering
5.2. Partnering events
5.3. Further reading on dealmaking
Appendix 1 - Deal type definitions
About Wildwood Ventures
Recent titles from CurrentPartnering
Order Form - Reports
Table of figures
Figure 1: Parkinson's disease partnering since 2007
Figure 2: Bigpharma - top 50 -Parkinson's disease deals 2007 to 2011
Figure 3: Bigpharma Parkinson's disease deal frequency - 2007 to 2011
Figure 4: Parkinson's disease partnering by deal type since 2007
Figure 5: Parkinson's disease partnering by industry sector since 2007
Figure 6: Parkinson's disease partnering by stage of development since 2007
Figure 7: Parkinson's disease partnering by technology type since 2007
Figure 8:Parkinson's disease deals with a headline value
Figure 9: Parkinson's disease deals with upfront payment values
Figure 10: Parkinson's disease deals with milestone payments
Figure 11: Parkinson's disease deals with royalty rates, %
Figure 12: Top Parkinson's disease deals by value since 2007
Figure 13: Top Parkinson's disease deals signed by bigpharma value since 2007
Figure 14: Online partnering resources
Figure 15: Forthcoming partnering events
Figure 16: Deal type definitions
The Parkinson's Disease Partnering 2007-2012 report provides understanding and access to the Parkinson's disease partnering deals and agreements entered into by the worlds leading healthcare companies.
Trends in Parkinson's disease partnering deals
Top Parkinson's disease deals by value
Deals listed by company A-Z, industry sector, stage of development, technology type